Structure-based drug design of selective Drp1 inhibitors
The mitochondrial protein dynamin-related protein (Drp1) has been implicated in the development of a number of diseases, including; cancer, heart disease and Alzheimer’s disease. To date, no direct small molecule drugs of human Drp1 have been identified. This project will use rational drug discovery techniques to develop these small molecule drugs. Namely, this project will design these drugs using in silico techniques, utilise medicinal chemistry to synthesise the drugs, and then test these drugs using both in vitro and cellular assays.
X-ray crystallography and site-directed mutagenesis will be conducted to get a complete understanding of how these drugs are interacting. Ultimately, this project will provide important research tools to reveal the specific role of Drp1 in disease and as potential leads for drug development.
Supervisors - Dr Christopher Langendorf: [email protected] and Dr Jessica HolienL [email protected]
Dr Christopher Langendorf
Protein chemistry & metabolism
For further information about this project, contact: